

Log
in

Register

Subscribe

Claim

Articles

Publish

About

Contact

Search for...

Advanced
searchRESEARCH ARTICLE | VOLUME 65,
ISSUE 2, P180-186, AUGUST 2009

Download Full Issue



Purchase



Share



Subscribe



Reprints



Save



Request

Differentiation between malignancy and inflammation in pulmonary ground-glass nodules: The feasibility of integrated ^{18}F -FDG PET/CT

Eun Ju Chun • Hyun Ju Lee • Won Jun Kang • ... Jin Mo Goo •
Chang Min Park • Chang Hyun Lee • Show all authors

Published: January 20, 2009 •

DOI: <https://doi.org/10.1016/j.lungcan.2008.11.015>

PlumX Metrics

Abstract

Abstract

ADVERTISEMENT

Keywords

Background

Reference

 ^{18}F -FDG PET/CT has been used to

s
Article info
Related
Articles

differentiate malignant solid lung nodules from benign nodules. We assess the feasibility of integrated ^{18}F -FDG PET/CT for the differentiation of malignancy from inflammation manifested as ground-glass nodules (GGNs) on chest CT.

Methods

A total of 68 GGNs in 45 patients (M:F = 24:21; mean age, 61) fulfilled the following criteria: (a) nodules composed of $\geq 50\%$ ground-glass opacity, (b) patients who underwent integrated PET/CT within 1 week following dedicated chest CT, (c) definitive diagnosis determined by pathological specimen or at least 9 months of follow-up, and (d) lesions ≥ 10 mm in diameter. 36 malignant GGNs were pathologically proved as adenocarcinoma ($n = 20$), bronchioloalveolar carcinoma ($n = 11$), low-grade lymphoma ($n = 3$), metastatic mucinous adenocarcinoma ($n = 1$) and unknown low-grade malignancy ($n = 1$). 32 inflammatory GGNs were confirmed as pneumonic infiltration as they had disappeared on follow-up CT and were associated with compatible clinical features ($n =$

26) or as chronic inflammation with fibrosis by VATS biopsy ($n = 6$). Using CT density histogram analysis, 14 were classified as pure GGNs and 54 as part-solid nodules. Integrated PET/CT was evaluated by measuring the maximum standardized uptake value (SUV) at the region of interest located at each lesion. The Mann–Whitney U test was performed to compare the SUV of malignancy and inflammation. The optimal cut-off value of SUV to differentiate malignancy from inflammation was determined using a receiver operating characteristic-based positive test. Sensitivity, specificity, accuracy, and positive predictive values (PPV) and negative predictive values (NPV) were calculated at the level of the optimal cut-off value. SUV showing 100% PPV for inflammatory GGNs was evaluated.

Results

In part-solid nodules, the maximum SUV was significantly higher in inflammation (2.00 ± 1.18 ; range, 0.48–5.60) than in malignancy (1.26 ± 0.71 ; range, 0.32–2.6) ($P = 0.018$). On the other hand, in pure GGNs, the

maximum SUV of malignancy (0.64 ± 0.19 ; range, 0.43–0.96) and inflammation (0.74 ± 0.28 ; range, 0.32–1.00) showed no difference ($P = 0.37$). Using the optimal cut-off value of SUV as 1.2 ($P = 0.01$) sensitivity, specificity, accuracy, PPV and NPV in part-solid nodules were 62.1%, 80.0%, 70.4%, 78.3% and 64.5%, respectively. Six part-solid nodules, which showed a maximum SUV of higher than 2.6, were all inflammations.

Conclusion

The part-solid nodules with positive FDG-PET could be inflammatory nodules rather than malignant nodules. This is a quite paradoxical result when considering the basic knowledge that malignant pulmonary nodules have higher glucose metabolism.

Keywords

[Ground-glass nodule](#) •

[Ground-glass opacity](#) • [GGN](#) • [GGO](#) •

[Solitary pulmonary nodules](#) • [PET/CT](#) •

[18F-FDG](#)

To read this article in full you will
need to make a payment

ESMO Member Login

Login with your ESMO username and
password.

► One-time access price info

Subscribe:

Subscribe to *Lung Cancer*

Purchase one-time access:

[Academic & Personal: 24 hour online
access](#)

[Corporate R&D Professionals: 24 hour
online access](#)

Already a print subscriber? [Claim online
access](#)

Already an online subscriber? [Sign in](#)

Register: [Create an account](#)

Institutional Access: [Sign in to
ScienceDirect](#)

References

1. Gould M.K. • Maclean C.C. •
Kuschnier W.G. • Rydzak C.E. •
Owens D.K.
**Accuracy of positron emission
tomography for diagnosis of
pulmonary nodules and mass
lesions: a meta-analysis.**
JAMA. 2001; **285**: 914-924

[View in Article](#) ^
[Scopus \(1022\)](#) • [PubMed](#) • [Crossref](#) •
[Google Scholar](#)
2. Kim S.K. • Allen-Auerbach M. •
Goldin J. • Fueger B.J. •
Dahlbom M. • Brown M. • et al.
**Accuracy of PET/CT in
characterization of solitary
pulmonary lesions.**
J Nucl Med. 2007; **48**: 214-220

[View in Article](#) ^
[PubMed](#) • [Google Scholar](#)
3. Kubota K.
**Changing pattern of lung
cancer and its imaging: (201)Tl
SPECT versus [(18)F]FDG PET.**
J Nucl Med. 2001; **42**: 1497-1498

[View in Article](#) [PubMed](#) • [Google Scholar](#)

4. Henschke C.I. • Yankelevitz D.F. • Mirtcheva R. • McGuinness G. • McCauley D. • Miettinen O.S. • ELCAP Group
CT screening for lung cancer: frequency and significance of part-solid and nonsolid nodules.
AJR Am J Roentgenol. 2002; **178**: 1053-1057

[View in Article](#) [Scopus \(816\)](#) • [PubMed](#) • [Crossref](#) • [Google Scholar](#)

5. Kim B.T. • Kim Y. • Lee K.S. • Yoon S.B. • Cheon E.M. • Kwon O.J. • et al.
Localized form of bronchioloalveolar carcinoma: FDG PET findings.
AJR Am J Roentgenol. 1998; **170**: 935-939

[View in Article](#) [Scopus \(149\)](#) • [PubMed](#) • [Crossref](#) • [Google Scholar](#)

6. Chang J.M. • Lee H.J. •
Goo J.M. • Lee H.Y. • Lee J.J. •
Chung J.K. • et al.

**False positive and false
negative FDG-PET scans in
various thoracic diseases.**

Korean J Radiol. 2006; **7**: 57-69

[View in Article](#) 

[Scopus \(254\)](#) • [PubMed](#) • [Crossref](#) •
[Google Scholar](#)

7. Kim T.J. • Lee K.W. • Kim H.Y. •
Lee J.H. • Kim E.A. • Kim S.K. •
et al.

**Simple pulmonary eosinophilia
evaluated by means of FDG
PET: the findings of 14 cases.**

Korean J Radiol. 2005; **6**: 208-
213

[View in Article](#) 

[Scopus \(14\)](#) • [PubMed](#) • [Crossref](#) •
[Google Scholar](#)

8. Nomori H. • Ohtsuka T. •
Naruke T. • Suemasu K.
**Histogram analysis of
computed tomography
numbers of clinical T1 N0 M0
lung adenocarcinoma, with**

**special reference to lymph
node metastasis and tumor
invasiveness.**

J Thorac Cardiovasc Surg. 2003;
126: 1584-1589

[View in Article](#) ^

[Scopus \(38\)](#) • [PubMed](#) • [Abstract](#) •

[Full Text](#) • [Full Text PDF](#) •

[Google Scholar](#)

9. Nomori H. • Watanabe K. •
Ohtsuka T. • Naruke T. •
Suemasu K. • Uno K.
**Evaluation of F-18
fluorodeoxyglucose (FDG) PET
scanning for pulmonary
nodules less than 3 cm in
diameter, with special reference
to the CT images.**

Lung Cancer. 2004; **45**: 19-27

[View in Article](#) ^

[Scopus \(292\)](#) • [PubMed](#) • [Abstract](#) •

[Full Text](#) • [Full Text PDF](#) •

[Google Scholar](#)

10. Patz Jr., E.F. • Lowe V.J. •
Hoffman J.M. • Paine S.S. •
Burrowes P. • Coleman R.E. •
et al.

**Focal pulmonary abnormalities:
evaluation with F-18
fluorodeoxyglucose PET
scanning.**

Radiology. 1993; **188**: 487-490

[View in Article](#) ^

[PubMed](#) • [Google Scholar](#)

11. Coleman R.E.
PET in lung cancer.
J Nucl Med. 1999; **40**: 814-820

[View in Article](#) ^

[PubMed](#) • [Google Scholar](#)

12. Hashimoto Y. • Tsujikawa T. •
Kondo C. • Maki M. •
Momose M. • Nagai A. • et al.
**Accuracy of PET for diagnosis
of solid pulmonary lesions with
¹⁸F-FDG uptake below the
standardized uptake value of
2.5.**
J Nucl Med. 2006; **47**: 426-431

[View in Article](#) ^

[PubMed](#) • [Google Scholar](#)

13. Lowe V.J. • Fletcher J.W. •
Gobar L. • Lawson M. •
Kirchner P. • Valk P. • et al.
**Prospective investigation of
positron emission tomography
in lung nodules.**
J Clin Oncol. 1998; **16**: 1075-1084

[View in Article](#) ^

[Scopus \(521\)](#) • [PubMed](#) • [Crossref](#) •

[Google Scholar](#)

14. Jones H.A. • Clark R.J. •
Rhodes C.G. • Schofield J.B. •
Krausz T. • Haslett C. • et al.
**In vivo measurement of
neutrophil activity in
experimental lung
inflammation.**
Am J Respir Crit Care Med. 1994;
149: 1635-1639

[View in Article](#) ^

[Scopus \(184\)](#) • [PubMed](#) • [Crossref](#) •

[Google Scholar](#)

15. Imdahl A. • Jenkner S. • Brink I. •
Nitzsche E. • Stoelben E. •
Moser E. • et al.
**Validation of FDG positron
emission tomography for**

**differentiation of unknown
pulmonary lesions.**

Eur J Cardiothorac Surg. 2001;
20: 324-329

[View in Article](#) ^

[Scopus \(56\)](#) • [PubMed](#) • [Crossref](#) •

[Google Scholar](#)

16. Deichen J.T. • Prante O. •
Gack M. • Schmiedehausen K. •
Kuwert T.
**Uptake of
[¹⁸F]fluorodeoxyglucose in
human monocyte-macrophages
in vitro.**
Eur J Nucl Med Mol Imaging.
2003; **30**: 267-273

[View in Article](#) ^

[Scopus \(118\)](#) • [PubMed](#) • [Crossref](#) •

[Google Scholar](#)

17. Higashi K. • Ueda Y. • Seki H. •
Yuasa K. • Oguchi M. •
Noguchi T. • et al.
**Fluorine-18-FDG PET imaging
is negative in
bronchioloalveolar lung
carcinoma.**
J Nucl Med. 1998; **39**: 1016-1020

[View in Article](#) 

[PubMed](#) • [Google Scholar](#)

18. Kuriyama K. • Seto M. • Kasugai T. • Higashiyama M. • Kido S. • Sawai Y. • et al.
Ground-glass opacity on thin-section CT: value in differentiating subtypes of adenocarcinoma of the lung.
AJR Am J Roentgenol. 1999; **173**: 465-469

[View in Article](#) 

[Scopus \(203\)](#) • [PubMed](#) • [Crossref](#) • [Google Scholar](#)

19. Berger K.L. • Nicholson S.A. • Dehdashti F. • Siegel B.A.
FDG PET evaluation of mucinous neoplasms: correlation of FDG uptake with histopathologic features.
AJR Am J Roentgenol. 2000; **174**: 1005-1008

[View in Article](#) 

[Scopus \(297\)](#) • [PubMed](#) • [Crossref](#) • [Google Scholar](#)

20. Koss M.N. • Hochholzer L. •
Nichols P.W. • Wehunt W.D. •
Lazarus A.A.

**Primary non-Hodgkin's
lymphoma and
pseudolymphoma of lung: a
study of 161 patients.**

Hum Pathol. 1983; **14**: 1024-1038

[View in Article](#) 

[Scopus \(182\)](#) • [PubMed](#) • [Abstract](#) •

[Full Text PDF](#) • [Google Scholar](#)

21. Dewan N.A. • Gupta N.C. •
Redepenning L.S. • Phalen J.J. •
Frick M.P.

**Diagnostic efficacy of PET-FDG
imaging in solitary pulmonary
nodules. Potential role in
evaluation and management.**

Chest. 1993; **104**: 997-1002

[View in Article](#) 

[Scopus \(341\)](#) • [PubMed](#) • [Crossref](#) •

[Google Scholar](#)

22. Townsend D.W. • Carney J.P. •
Yap J.T. • Hall N.C.

PET/CT today and tomorrow.

J Nucl Med. 2004; **45**: 4S-14S

[View in Article](#) [PubMed](#) • [Google Scholar](#)

23. Lee H.J. • Goo J.M. • Lee C.H. •
Yoo C.G. • Kim Y.T. • Im J.G.

**Nodular ground-glass opacities
on thin-section CT: size change
during follow-up and
pathological results.**

Korean J Radiol. 2007; **8**: 22-31

[View in Article](#) [Scopus \(100\)](#) • [PubMed](#) • [Crossref](#) •
[Google Scholar](#)

24. Zhuang H. • Pourdehnad M. •
Lambright E.S. • Yamamoto A.J. •
Lanuti M. • Li P. • et al.

**Dual time point ¹⁸F-FDG PET
imaging for differentiating
malignant from inflammatory
processes.**

J Nucl Med. 2001; **42**: 1412-1417

[View in Article](#) [PubMed](#) • [Google Scholar](#)

Article info

Publication history

Published online: January 20, 2009

Accepted: November 20, 2008

Received in revised form: November 17, 2008

Received: October 6, 2008

Identification

DOI:

<https://doi.org/10.1016/j.lungcan.2008.11.015>

Copyright

© 2008 Elsevier Ireland Ltd.

Published by Elsevier Inc. All rights reserved.

ScienceDirect

[Access this article on ScienceDirect](#)

Related Articles

[Joint use of the radiomics method and frozen sections should be considered in the prediction of the final classification of peripheral lung adenocarcinoma manifesting as ground-glass nodules](#)

Wang et al.

Lung Cancer, November 14, 2019

[Preview](#) • [Full-Text](#) • [PDF](#)

[The additional diagnostic value of virtual bronchoscopy navigation in patients with pulmonary nodules – The NAVIGATOR study](#)

Hiddinga et al.

Lung Cancer, January 23, 2023

[Preview](#) • [Full-Text](#) • [PDF](#)

[Open Access](#)

[Imaging features of TSCT predict the classification of pulmonary preinvasive lesion, minimally and invasive adenocarcinoma presented as ground glass nodules](#)

Liu et al.

Lung Cancer, March 27, 2017

[Preview](#) • [Full-Text](#) • [PDF](#)

[Tumor autoantibodies \(TAAs\) panel can improve the accuracy of early diagnosis in lung cancer presenting with ground-glass nodules \(GGNs\) in Chinese population](#)

He et al.

Lung Cancer, February 9, 2018

[Preview](#) • [Full-Text](#) • [PDF](#)

[Induction and preliminary
characterization of neoplastic
pulmonary nodules in a transgenic pig
model](#)

Ghosn et al.

Lung Cancer, February 21, 2023

[Preview](#) • [Full-Text](#) • [PDF](#)

[View full text](#)

[Home](#)

[Access for Developing Countries](#)

ARTICLES AND ISSUES

[Articles in Press](#)

[Current Issue](#)

[List of Issues](#)

FOR AUTHORS

[About Open Access](#)

[Author Information](#)

[Permissions](#)

[Researcher Academy](#)

[Submit a Manuscript](#)

JOURNAL INFO

[About Open Access](#)

[About the Journal](#)

[Abstracting/Indexing](#)

[Information for Advertisers](#)

[Career Opportunities](#)

[Contact Information](#)

[Editorial Board](#)

[Pricing](#)

[New Content Alerts](#)

SUBSCRIBE

SOCIETY INFO

[European Society for Medical Oncology \(ESMO\)](#)

[European Thoracic Oncology Platform \(ETOP\) and International Breast Cancer Study Group \(IBCSG\) Partners Foundation](#)

[British Thoracic Oncology Group \(BTOG\)](#)

MORE PERIODICALS

[Find a Periodical](#)

[Go to Product Catalog](#)

The content on this site is intended for healthcare professionals.

We use cookies to help provide and enhance our service and tailor content. To update your cookie settings, please visit the [Cookie settings](#) | [Your Privacy Choices](#) for this site.

All content on this site: Copyright © 2024 Elsevier Inc., its licensors, and contributors.

All rights are reserved, including those for text and data mining, AI training, and similar technologies.

For all open access content, the Creative Commons licensing terms apply.

[Privacy Policy](#) [Terms and Conditions](#) [Accessibility](#) [Help & Contact](#)

